Radiofrequency ablation in combination with hepatic resection for colorectal liver metastases

概要

論文の詳細を見る
In the era of new chemotherapy, therapeutic efficacies of radiofrequency ablation (RFA) combined with hepatic resection for colorectal liver metastases (CRLM) are summarized. In the literatures, local recurrence rates per patient ranged from 5% to17.4%. The 3- and 5-year survival rates ranged from 38% to 47%, and 47% to 68%, respectively. In our department, from 2005 to 2009, 26 initially unresectable CRLM patients were downstaged to be resectable with chemotherapy including FOLFOX. Local recurrence was observed only in one tumor (2.5%) in 31 months. In hepatectomy only group and RFA-combination group, progression-free survivals were 21 and 23 months and overall survivals were not reached and 36 months, respectively. Synchronous RFA with hepatic resection should be selected at the timing of destruction of all CRLMs after appropriate chemotherapy.